Given the dearth of evidence regarding the impact of CRi, CRp, or CRh on mutation clearance after FLT3 inhibitor therapy in patients with FLT3‐ITD+ AML, further evaluation of these responses is clearly warranted. Here, FLT3 is linked to acute myeloid leukemia.